Evaluation of immunosuppressive regimens in kidney transplanted patients in Iraq

Dr. Hemen Faik Mohammad
Dr. Hemen Faik Mohammad * §
Contact
§ hawler medical university

Send Message

To: Author

Evaluation of immunosuppressive regimens in kidney transplanted patients in Iraq

Article Fingerprint

ReserarchID

MR11WD4

Evaluation of immunosuppressive regimens in kidney transplanted patients in Iraq Banner

Key Research Insights

Synthesized scholarly intelligence & interactive research assistant
Access Review Comments
  • English
  • Afrikaans
  • Albanian
  • Amharic
  • Arabic
  • Armenian
  • Azerbaijani
  • Basque
  • Belarusian
  • Bengali
  • Bosnian
  • Bulgarian
  • Catalan
  • Cebuano
  • Chichewa
  • Chinese (Simplified)
  • Chinese (Traditional)
  • Corsican
  • Croatian
  • Czech
  • Danish
  • Dutch
  • Esperanto
  • Estonian
  • Filipino
  • Finnish
  • French
  • Frisian
  • Galician
  • Georgian
  • German
  • Greek
  • Gujarati
  • Haitian Creole
  • Hausa
  • Hawaiian
  • Hebrew
  • Hindi
  • Hmong
  • Hungarian
  • Icelandic
  • Igbo
  • Indonesian
  • Irish
  • Italian
  • Japanese
  • Javanese
  • Kannada
  • Kazakh
  • Khmer
  • Korean
  • Kurdish (Kurmanji)
  • Kyrgyz
  • Lao
  • Latin
  • Latvian
  • Lithuanian
  • Luxembourgish
  • Macedonian
  • Malagasy
  • Malay
  • Malayalam
  • Maltese
  • Maori
  • Marathi
  • Mongolian
  • Myanmar (Burmese)
  • Nepali
  • Norwegian
  • Pashto
  • Persian
  • Polish
  • Portuguese
  • Punjabi
  • Romanian
  • Russian
  • Samoan
  • Scots Gaelic
  • Serbian
  • Sesotho
  • Shona
  • Sindhi
  • Sinhala
  • Slovak
  • Slovenian
  • Somali
  • Spanish
  • Sundanese
  • Swahili
  • Swedish
  • Tajik
  • Tamil
  • Telugu
  • Thai
  • Turkish
  • Ukrainian
  • Urdu
  • Uzbek
  • Vietnamese
  • Welsh
  • Xhosa
  • Yiddish
  • Yoruba
  • Zulu
Reading Preferences
Font Size
Line Spacing
Background

Abstract

Immunosuppressive regimens with the fewest possible toxic effects are desirable for transplant recipients. This study evaluated the efficacy and relative toxic effects of three immunosuppressive regimens used after kidney transplantation in Kirkuk city. 52 kidney transplanted patients were enrolled in this study and categorized into three treatment groups. The group I patients received standard-dose of CsA, MMF in combinations with prednisolone, and the group II patients received low-dose CsA, Aza in combinations with prednisolone, while the group III patients received low-dose Tac, MMF in combinations with prednisolone. The primary efficacy end point was the renal function; secondary end points were incidence of serious adverse effects and the complication of immunosuppression therapy in transplanted recipient.

References

82 Cites in Article
  1. A Saracino,G Santarsia,A Latorraca,V Gaudiano (2006). Early assessment of renal resistance index after kidney transplant can help predict long-term renal function.
  2. Anand Khurana,Daniel Brennan (2011). Current Concepts of Immunosuppression and Side Effects.
  3. Angela Webster,Rod Taylor,Jeremy Chapman,Jonathan Craig (2009). Tacrolimus versus cyclosporin as primary immunosuppression for kidney transplant recipients.
  4. P Halloran (2004). Immunosuppressive drugs for kidney transplantation.
  5. T Rainienë (2005). Immunosuppression in the past and today.
  6. W Bennett,De Mattos,A Meyer,M Andoh,T Barry,J (1996). Chronic cyclosporine nephropathy in renal transplantation.
  7. M Denton,C Magee,M Sayegh (1999). Immunosuppressive strategies in transplantation.
  8. A Chan,O Stüve,N Von Ahsen (2008). Immunosuppression in clinical practice: approaches to individualized therapy.
  9. B Nankivell,J Richard,R Borrows,Cl-S Fung (2003). The natural history of chronic allograft nephropathy.
  10. Titte Srinivas,Bruce Kaplan,Herwig-Ulf Meier-Kriesche (2003). Mycophenolate mofetil in solid-organ transplantation.
  11. H Sollinger (1995). MYCOPHENOLATE MOFETIL FOR THE PREVENTION OF ACUTE REJECTION IN PRIMARY CADAVERIC RENAL ALLOGRAFT RECIPIENTS.
  12. G Levy (2001). Long-term immunosuppression and drug interactions.
  13. Titte Srinivas,Herwig-Ulf Meier-Kriesche (2008). Minimizing Immunosuppression, an Alternative Approach to Reducing Side Effects.
  14. Gabriel Danovitch (2005). Immunosuppressive medications for renal transplantation: A multiple choice question.
  15. B Kasiske,M Vazques,W Harmon (2000). Recommendations for the Outpatient Surveillance of Renal Transplant Recipients.
  16. J Stephen,T Pearson,L Gallon (2007). Evolving strategies for immunosuppression in renal transplantation: A review of recent clinical trials.
  17. M Puigmule,J Lopez-Hellin,G Sune,O Tornavaca (2009). Differential proteomic analysis of cyclosporine Ainduced toxicity in renal proximal tubule cells.
  18. A Trull,K Hue,K Tan,S Gore,S Whitewood,R Smyth,J Scott,C Price,J Wallwork (1990). Cross-correlation of cyclosporine concentrations and biochemical measures of kidney and liver function in heart and heart-lung transplant recipients.
  19. J Bauer,C Brooks,R Burch (1982). Clinical appraisal of creatinine clearance as a measurement of glomerular filtration rate.
  20. B Kahan (1987). Immunosuppressive therapy with cyclosporine for cardiac transplantation..
  21. C Wissmann,F Frey,P Ferrari,D Uehlinger (1996). Acute cyclosporine-induced nephrotoxicity in renal transplant recipients.
  22. J Karamehic,M Asceric,S Rakic (1997). Adverse reactions of cyclosporine in patients after kidney transplantation.
  23. José Morales,Amado Andres,Manuel Rengel,José Rodicio (2001). Influence of cyclosporin, tacrolimus and rapamycin on renal function and arterial hypertension after renal transplantation.
  24. C Ponticelli (2005). Cyclosporine: from renal transplantation to autoimmune diseases.
  25. D Van Buren,J Burke,R Lewis (1994). Renal function in patients receiving long-term cyclosporine therapy.
  26. M Lassila (2000). Cyclosporine A-induced hypertension and nephrotoxicity in spontaneously hypertensive rats on high-sodium diet.
  27. Daniel Abramowicz,Maria Del Carmen Rial,Stefan Vitko,Domingo Del Castillo,Derek Manas,Mieczyslaw Lao,Nesrin Gafner,Peter Wijngaard (2005). Cyclosporine Withdrawal from a Mycophenolate Mofetil–Containing Immunosuppressive Regimen.
  28. S Takemoto,B Pinsky,M Schnitzler,K Lentine,L Willoughby,T Burroughs,S Bunnapradist (2007). A Retrospective Analysis of Immunosuppression Compliance, Dose Reduction and Discontinuation in Kidney Transplant Recipients.
  29. H Ekberg,H Tedesco-Silva,A Demirbas,S Vitko,B Nashan (2007). Reduced exposure to calcineurin inhibitors in renal transplantation.
  30. Gabriella Moroni,Andrea Doria,Marta Mosca,Ornella Alberighi,Gianfranco Ferraccioli,Silvano Todesco,Carlo Manno,Paolo Altieri,Roberto Ferrara,Simona Greco,Claudio Ponticelli (2006). A Randomized Pilot Trial Comparing Cyclosporine and Azathioprine for Maintenance Therapy in Diffuse Lupus Nephritis over Four Years.
  31. Norma Bobadilla,Gerardo Gamba (2007). New insights into the pathophysiology of cyclosporine nephrotoxicity: a role of aldosterone.
  32. Bernhard Krämer,Giuseppe Montagnino,Domingo Del Castillo,Raimund Margreiter,Heide Sperschneider,Christoph Olbricht,Bernd Krüger,Joaquín Ortuño,Hans Köhler,Ulrich Kunzendorf,Hans-Krister Stummvoll,Jose Tabernero,Ferdinand Mühlbacher,Manuel Rivero,Manuel Arias (2005). Efficacy and safety of tacrolimus compared with cyclosporin A microemulsion in renal transplantation: 2 year follow-up results.
  33. M Artz,J Boots,G Ligtenberg (2003). Improved cardiovascular risk profile and renal function in renal transplant patients after randomized conversion from cyclosporine to tacrolimus.
  34. Maarten Naesens,Dirk Kuypers,Minnie Sarwal (2009). Calcineurin Inhibitor Nephrotoxicity.
  35. Jose Morales,Beatriz Domínguez-Gil (2006). Impact of Tacrolimus and Mycophenolate Mofetil Combination on Cardiovascular Risk Profile after Kidney Transplantation.
  36. A Jurewicz (2003). Tacrolimus versus ciclosporin immunosuppression: long-term outcome in renal transplantation.
  37. Rachel Becker-Cohen,Amiram Nir,Choni Rinat,Sofia Feinstein,Nurit Algur,Benjamin Farber,Yaacov Frishberg (2006). Risk Factors for Cardiovascular Disease in Children and Young Adults after Renal Transplantation.
  38. N Ichimaru,S Takahara,Y Kokado,J Wang,M Hatori,H Kameoka,Inouet,A Okuyama (2001). Changes in lipid metabolism and effect of simvastatin in renal transplant recipients induced by cyclosporine or tacrolimus.
  39. C Wanner,T Quaschning (2001). Abnormal lipid metabolism after renal transplantation.
  40. B Kasiske,F Cosio,J Beto,K Bolton,B Chavers,R Grimm,A Levin,B Masri,R Parekh,C Wanner,D Wheeler,P Wilson (2004). Clinical practice guidelines for managing dyslipidemias in kidney transplant patients: a report from the Managing Dyslipidemias in Chronic Kidney Disease Work Group of the National Kidney Foundation Kidney Disease Outcomes Quality Initiative.
  41. T Ilgenli,G Atilla,M Cirit,N Azmak (1999). The role of serum lipids on Cyclosporine-induced gingival overgrowth in renal transplant patients.
  42. Nosratola Vaziri,Kaihui Liang,Habib Azad (2000). Effect of Cyclosporine on HMG-CoA Reductase, Cholesterol 7α-Hydroxylase, LDL Receptor, HDL Receptor, VLDL Receptor, and Lipoprotein Lipase Expressions.
  43. M Hami,M Mojahedi,M Naghibi,M Shakeri,F Sharifipour (2010). Cyclosporine trough levels and its side effects in kidney transplant recipients.
  44. L Hilbrands,P Demacker,A Hoitsma,A Stalenhoef,R Koene (1995). The effects of cyclosporine and prednisone on serum lipid and (apo)lipoprotein levels in renal transplant recipients..
  45. Ahmed Hamdy,Mohamed Bakr,Mohamed Ghoneim (2008). Long-term Efficacy and Safety of a Calcineurin Inhibitor-free Regimen in Live-Donor Renal Transplant Recipients.
  46. Richard Moore,Domingo Hernandez,Hannah Valantine (2001). Calcineurin Inhibitors and Post-Transplant Hyperlipidaemias.
  47. Lesley Scott,Kate Mckeage,Susan Keam,Greg Plosker (2003). Tacrolimus.
  48. John Pirsch,Joshua Miller,Mark Deierhoi,Flavio Vincenti,Ronald Filo (1997). A COMPARISON OF TACROLIMUS (FK506) AND CYCLOSPORINE FOR IMMUNOSUPPRESSION AFTER CADAVERIC RENAL TRANSPLANTATION1.
  49. Thomas Mccune,Leroy Thacker,Thomas Peters,Laura Mulloy,Michael Rohr,Patricia Adams,Jackson Yium,Jimmy Light,Timothy Pruett,A Gaber,Steven Selman,Johann Jonsson,Joseph Hayes,Francis Wright,Thomas Armata,Jack Blanton,James Burdick (1998). EFFECTS OF TACROLIMUS ON HYPERLIPIDEMIA AFTER SUCCESSFUL RENAL TRANSPLANTATION.
  50. Gerry Ligtenberg,Ronald Hené,Peter Blankestijn,Hein Koomans (2001). Cardiovascular Risk Factors in Renal Transplant Patients.
  51. Matthew Jose (2007). Calcineurin inhibitors in renal transplantation: adverse effects.
  52. T Oto,M Okazaki,K Takata,M Egi,M Yamane (2010). Calcineurin inhibitor-related cholestasis complicating lung transplantation.
  53. Nobuhiko Taniai,Koho Akimaru,Yosinori Ishikawa,Tomohiro Kanada,Daisuke Kakinuma,Yoshiaki Mizuguchi,Yasuhiro Mamada,Hiroshi Yoshida,Takashi Tajiri (2008). Hepatotoxicity Caused by Both Tacrolimus and Cyclosporine after Living Donor Liver Transplantation.
  54. Y Shakiba,A Mostafaie,D Arshadi,B Sabayan (2009). Application of garlic organosulfur compounds in prevention of cyclosporine A-induced hepatotoxicity.
  55. R Schade,A Guglielmi,Van Thiel,D (1983). Cholestasis in heart transplant recipient treated with cyclosporine.
  56. J Cadranel,S Erlinger,M Desruenne,J Luciani,F Lunel,P Grippon,A Cabrol,P Opolon (1992). Chronic administration of cyclosporin A induces a decrease in hepatic excretory function in man.
  57. Manfred Hecking,Alexander Kainz,Martin Schillinger,Christian Posch,Tudor Birsan,Susanne Rasoul-Rockenschaub,Georg Böhmig,Sabine Schmaldienst,Bruno Watschinger,Walter Hörl,Ferdinand Mühlbacher,Marcus Säemann (2008). Analysis of liver function in renal transplant recipients undergoing C2-monitoring for cyclosporine.
  58. W Finn,G Porter (2008). Urinary biomarkers and nephrotoxicity: Clinical Nephrotoxins: Renal Injury from Drugs and Chemicals 3th Edition. Springer Science; 92-117. nephrotoxicity: A role of aldosterone.
  59. Uwe Christians,Karl-Friedrich Sewing (1995). Alternative cyclosporine metabolic pathways and toxicity.
  60. Marc Lorber,Charles Van Buren,Stuart Flechner,Chris Williams,Barry Kahan (1987). HEPATOBILIARY AND PANCREATIC COMPLICATIONS OF CYCLOSPORINE THERAPY IN 466 RENAL TRANSPLANT RECIPIENTS.
  61. B Gulbis,M Adler,H Ooms,J Desmet,J Leclerc,G Primo (1988). Liver-function studies in heart-transplant recipients treated with cyclosporin A..
  62. Patricia Delgado,Juan Diaz,Irene Silva,Jose[combining Osorio,Antonio Osuna,Beatriz Baye[combining Acute Accent]s,Ricardo Lauzurica,Edgar Arellano,Jose Campistol,Rosa Dominguez,Carlos Go[combining Acute Accent]mez-Alamillo,Meritxell Ibernon,Francisco Moreso,Rocio Benitez,Ildefonso Lampreave,Esteban Porrini,Armando Torres (2008). Unmasking Glucose Metabolism Alterations in Stable Renal Transplant Recipients.
  63. Johannes Boots,Elly Van Duijnhoven,Maarten Christiaans,Bruce Wolffenbuttel,Johannes Van Hooff (2002). Glucose Metabolism in Renal Transplant Recipients on Tacrolimus.
  64. Michael Crutchlow,Roy Bloom (2007). Transplant-Associated Hyperglycemia.
  65. S Chadban (2008). New-onset diabetes after transplantation-should it be a factor in choosing an immunosuppressant regimen for kidney transplant recipients.
  66. A Teutonico,P Schena,Di Paolo,S (2005). Glucose metabolism in renal transplant recipients: Effect of Calcineurin Inhibitor withdrawal and conversion to sirolimus.
  67. Thomas Burroughs,Krista Lentine,Steve Takemoto,Jason Swindle,Gerardo Machnicki,Karen Hardinger,Daniel Brennan,William Irish,Mark Schnitzler (2007). Influence of Early Posttransplantation Prednisone and Calcineurin Inhibitor Dosages on the Incidence of New-Onset Diabetes.
  68. Angela Webster,Rebecca Woodroffe,Rod Taylor,Jeremy Chapman,Jonathan Craig (2005). Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: meta-analysis and meta-regression of randomised trial data.
  69. Guido Filler,Ines Neuschulz,Ilka Vollmer,Peter Amendt,Berthold Hocher (2000). Tacrolimus reversibly reduces insulin secretion in paediatric renal transplant recipients.
  70. F Vincenti,S Friman,E Scheuermann,L Rostaing (2007). Results of an international randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus.
  71. O Johnston,C Rose,A Webster,J Gill (2008). Sirolimus Is Associated with New-Onset Diabetes in Kidney Transplant Recipients.
  72. Mads Hornum,Kaj Jørgensen,Jesper Hansen,Finn Nielsen,Karl Christensen,Elisabeth Mathiesen,Bo Feldt-Rasmussen (2010). New-Onset Diabetes Mellitus after Kidney Transplantation in Denmark.
  73. J Van Hooff,M Christiaans,E Van Duijnhoven (2004). Evaluating mechanisms of post-transplant diabetes mellitus.
  74. A Hooda,A Kumar,P Varma (2007). Tacrolimus dose in renal transplantation -do we have an answer.
  75. S Taler,S Textor,V Canzanello,L Schwartz (1999). Cyclosporine-induced hypertension: incidence, pathogenesis and management.
  76. I Wahba,W Bennett (2007). Increased vascular resistance and not salt retention characterizes cyclosporine A-induced hypertension: report in an anuric patient.
  77. Jose Castillo-Lugo,Pedro Vergne-Marini (2005). Hypertension in Kidney Transplantation.
  78. Paolo Catarsi,Roberto Ravazzolo,Francesco Emma,Doriana Fruci,Livio Finos,Andrea Frau,Giacomo Morreale,Alba Carrea,Gian Ghiggeri (2005). Angiotensin-converting enzyme (ACE) haplotypes and cyclosporine A (CsA) response: a model of the complex relationship between ACE quantitative trait locus and pathological phenotypes.
  79. Peter Schnuelle,Jaap Van Der Heide,Adam Tegzess,Cornelis Verburgh,Leendert Paul,Fokko Van Der Woude,Johan De Fijter (2002). Open Randomized Trial Comparing Early Withdrawal of either Cyclosporine or Mycophenolate Mofetil in Stable Renal Transplant Recipients Initially Treated with a Triple Drug Regimen.
  80. D Ciavarella,R Guiglia,G Campisi,Di Cosola,M (2007). Update on gingival overgrowth by cyclosporine A in renal transplants.
  81. F Erdmann,M Weiwad,S Kilka,M Karanik (2010). The Novel Calcineurin Inhibitor CN585 has potent immunosuppressive properties in stimulated human T Cells.
  82. H Ko,E Greanya,T Lee (2008). Mycophenolate mofetil in liver transplant patients with calcineurin-inhibitor-induced renal impairment.
Show All References
Download References

Funding

No external funding was declared for this work.

Conflict of Interest

The authors declare no conflict of interest.

Ethical Approval

No ethics committee approval was required for this article type.

Data Availability

Not applicable for this article.

How to Cite This Article

Dr. Hemen Faik Mohammad. 1970. "Evaluation of immunosuppressive regimens in kidney transplanted patients in Iraq". Global Journal of Medical Research - B: Pharma, Drug Discovery, Toxicology & Medicine GJMR-B Volume 12 (GJMR Volume 12 Issue B1).

More Citation Formats

Download Citation

  • Open Access
  • CC-BY-ND-NC 4.0
Download Article
Access OJS
Journal Specifications

Crossref Journal DOI 10.17406/gjmr

Print ISSN 0975-5888

e-ISSN 2249-4618

Keywords
Aza= AzathioprineCNI= Calcineurin inhibitorCsA= Cyclosporine AMMF= Mycophenolate mofetilTac= Tacrolimus
Classification
GJMR-B Classification NLMC Code: WJ 368
QY 175
WJ 378
  • Submission ReceivedDecember 10, 2011
  • Peer Review Double Blind
    Handling Editor
  • Accepted January 3, 2012
  • Published January 16, 2012
Version of record

v1.2

Language
English
Order Article Reprint
Experiance in AR

Explore published articles in an immersive Augmented Reality environment. Our platform converts research papers into interactive 3D books, allowing readers to view and interact with content using AR and VR compatible devices.

View in VR
Read in 3D

Your published article is automatically converted into a realistic 3D book. Flip through pages and read research papers in a more engaging and interactive format.

View in 3D
Article Matrices
Total Views: 8.4K
Total Downloads: 458
All Trends

Request Access

Please fill out the form below to request access to this research paper. Your request will be reviewed by the editorial or author team.
X

This is the heading

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

High-quality academic research articles on global topics and journals.

Evaluation of immunosuppressive regimens in kidney transplanted patients in Iraq

Dr. Mohammad
Dr. Mohammad hawler medical university
  • Submission ReceivedDecember 10, 2011
  • Peer Review Double Blind
    Handling Editor
  • Accepted January 3, 2012
  • Published January 16, 2012